The hurdle of antiandrogen drug resistance: Drug design strategies

Expert Opinion on Drug Discovery

Volumn 8, Issue 12, 2013, Pages 1491-1501

  Trendel, Jill A ^a  

^a UNIVERSITY OF TOLEDO   (United States)

Author keywords

Androgen independent; Antiandrogens; Castrate resistant prostate cancer; Metastatic prostate cancer; Prostate cancer therapy

Indexed keywords

4SC 205; ABARELIX; ABIRATERONE ACETATE; ANTIANDROGEN; ATRASENTAN; BICALUTAMIDE; CABAZITAXEL; CARBOPLATIN; CETRORELIX; CISPLATIN; COLCHICINE; DASATINIB; DEGARELIX; DENOSUMAB; DOCETAXEL; DOXORUBICIN; ENZALUTAMIDE; ESTRAMUSTINE; GOSERELIN; KETOCONAZOLE; KINESIN INHIBITOR; LEUPRORELIN; MITOXANTRONE; ORTERONEL; OXALIPLATIN; PREDNISONE; SATRAPLATIN; SIPULEUCEL T; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOLEDRONIC ACID; ZOPTARELIN DOXORUBICIN;

ABSENCE OF SIDE EFFECTS; ANTIANDROGEN THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNIZATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL TRIAL (TOPIC); DRUG BINDING; DRUG DESIGN; DRUG EFFICACY; DRUG STRUCTURE; GENE EXPRESSION; GOLD STANDARD; HUMAN; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; REVIEW; TRANSCRIPTION INITIATION; UNSPECIFIED SIDE EFFECT;

ANDROGEN ANTAGONISTS; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 84889030775     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2013.855194     Document Type: Review

References (87)

1. Prostate Cancer. Available from: http:// www.cancer.gov/cancertopics/ types/ prostate [Last accessed 9 July 2013]
2. Prostate cancer: incidence and mortality. Available from: http://www. cancerresearchuk.org/cancer-info/ cancerstats/world/prostate-cancer-world/ [Last accessed 9 July 2013]
3. Survival rates for prostate cancer. 5/15/ 2013 Available from: http://www.cancer. org/cancer/prostatecancer/detailedguide/ prostate-cancer- survival-rates [Last accessed 9 July 2013]
4. Armstrong A, Febbo P. Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature. Oncologist 2009;14:816-27
5. Armstrong AJ, Garrett-Mayer E, Ou Yang YC, et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 2007;25(25):3965-70 (Pubitemid 47477275)
6. Miles AK, Rogers A, Parkinson R, et al. Overview of prostate biomarkers as potential targets for immunotherapy. Curr Cancer Ther Rev 2008;4:86-95
7. Armstrong AJ, Garrett-Mayer ES, Yang YC, et al. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 2007;13(21):6396-403 (Pubitemid 350075029)
8. Scher HI, Warren M, Heller G. The association between measures of progression and survival in castrate-metastatic prostate cancer. Clin Cancer Res 2007;13(5):1488-92 (Pubitemid 46450439)
9. Halabi S, Vogelzang NJ, Ou SS, et al. Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. J Clin Oncol 2009;27(17):2766-71
10. Vessella RL, Corey E. Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis. Clin Cancer Res 2006;12(20 pt2):6285s-90s (Pubitemid 44703804)
11. Msaouel P, Pissimissis N, Halapas A, et al. Mechanisms of bone metastasis in prostate cancer: clinical implications. Best Pract Res Clin Endocrinol Metab 2008;22(2):341-55 (Pubitemid 351611957)
12. De Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008;14(19):6302-9
13. Amato RJ, Melinkova V, Zhang Y, et al. Epithelial cell adhesion molecule-positive circulating tumor cells as predictive biomarker in patients with prostate cancer. Urology 2013;81(6):1303-7
14. Alifrangis C, O'Hanlon-Brown C, Tuthill M, et al. New drugs for prostate cancer. BJU Int 2012;109(12):1801-6
15. Attar R, Takimoto C, Gottardis M. Castration-resistant prostate cancer: locking up the molecular escape routes. Clin Cancer Res 2009;15(10):3251-5
16. Brinkmann A, Kuiper GGJM, Ris-Stalpers C, et al. Androgen receptor abnormalities. J Steroid Biochem Mol Biol 1991;40:349-52
17. Schmidt L, Tindall D. Androgen receptor: past, present, and future. Curr Drug Targets 2013;14:401-7
18. Semenas J, Allegrucci C, Boorjian SA, et al. Overcoming drug resistance and treating advanced prostate cancer. Curr Drug Targets 2012;13:1308-23
19. Simental J, Sar M, Lane MV, et al. Transcriptional activation and nuclear targeting signals of the human androgen receptor. J Biol Chem 1991;266(1):510-18 (Pubitemid 21906153)
20. Brinkmann A, Jenster G, Kuiper GG, et al. The human androgen receptor: structure/function relationship in normal and pathological situations. J Steroid Biochem Mol Biol 1992;41:361-8
21. Culig Z, Klocker A, Bartsch G, et al. Androgen receptors in prostate cancer. Endocr Relat Cancer 2002;9:155-70 (Pubitemid 35175976)
22. Mellado B, Codony J, Ribal MJ, et al. Molecular biology of androgen-independent prostate cancer: the role of the androgen receptor pathway. Clin Transl Oncol 2009;11:5-10
23. Lack NA, Axerio-Cilies P, Tavassoli P, et al. Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening. J Med Chem 2011;54(24):8563-73
24. Heemers HV, Tindall DJ. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 2007;28(7):778-808 (Pubitemid 350294296)
25. van deWijngaart DJ, Dubbink HJ, van Royen ME, et al. Androgen receptor coregulators: recruitment via the coactivator binding groove. Mol Cell Endocrinol 2012;352(1-2):57-69
26. Dehm SM, Tindall DJ. Molecular regulation of androgen action in prostate cancer. J Cell Biochem 2006;99(2):333-44 (Pubitemid 44435552)
27. Grasso C, Wu YM, Robinson DR, et al. The mutational landscape of lethal castrate resistant prostate cancer. Nature 2012;487(7406):239-43
28. Lonergan PE, Tindall DJ. Androgen receptor signaling in prostate cancer development and progression. J Carcinog 2011;1020
29. Mangerini R, Argellati F, Pfeffer U, et al. Effects of bicalutamide and 4OH-tamoxifen on androgen-regulated gene expression in the LNCaP cell line. Anticancer Res 2012;32(12):5323-9
30. Wang L, Tang H, Thayanithy V, et al. Gene networks and microRNAs implicated in aggressive prostate cancer. Cancer Res 2009;69(24):9490-7
31. Lattouf JB, Srinivasan R, Pinto PA, et al. Mechanisms of disease: the role of heat-shock protein 90 in genitourinary malignancy. Nat Clin Pract Urol 2006;3(11):590-601 (Pubitemid 44698094)
32. Migliaccio A, Castoria G, Auricchio F. Analysis of androgen receptor rapid actions in cellular signaling pathways: receptor/Src association. Methods Mol Biol 2011;776:361-70
33. Carver BS, Chapinski C, Wongvipat J, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011;19(5):575-86
34. Majumder PK, Sellers WR. Akt-regulated pathways in prostate cancer. Oncogene 2005;24(50):7465-74 (Pubitemid 41637986)
35. Carrion-Salip D, Panosa C, Menendez JA, et al. Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands. Int J Oncol 2012;41(3):1128-38
36. Tantivejkul K, Loberg RD, Mawocha SC, et al. PAR1-mediated NFkappaB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism. J Cell Biochem 2005;96(3):641-52 (Pubitemid 41504661)
37. Ghosh PM, Malik SN, Bedolla RG, et al. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation. Endocr Relat Cancer 2005;12(1):119-34 (Pubitemid 40477093)
38. Sarker D, Reid AH, Yap TA, et al. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 2009;15(15):4799-805
39. Karhadkar SS, Bova GS, Abdallah N, et al. Hedgehog signaling in prostate regeneration, neoplasia and metastasis. Nature 2004;431:707-12 (Pubitemid 39382619)
40. Gonnissen A, Isebaert S, Haustermans K. Hedgehog signaling in prostate cancer and its therapeutic implication. Int J Mol Sci 2013;14(7):13979-134007
41. Efstathiou E, KarlouM, Wen S, et al. Integrated Hedgehog signaling is induced following castration in human and murine prostate cancers. Prostate 2013;73(2):153-61
42. Yu J, Yu J, Mani RS, et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 2010;17(5):443-54
43. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310(5748):644-8 (Pubitemid 41528150)
44. Lin B, Ferguson C, White JT, et al. Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res 1999;59(17):4180-4 (Pubitemid 29418721)
45. Shah S, Hess-Wilson JK, Webb S, et al. 2,2-bis(4-chlorophenyl)- 1,1-dichloroethylene stimulates androgen independence in prostate cancer cells through combinatorial activation of mutant androgen receptor and mitogen-activated protein kinase pathways. Mol Cancer Res 2008;6(9):1507-20
46. Steketee K, Timmerman L, Ziel-van der Made AC, et al. Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancer. Int J Cancer 2002;100(3):309-17 (Pubitemid 34728989)
47. Maggiolini M, Vivacqua A, Carpino A, et al. The mutant androgen receptor T877A mediates the proliferative but not the cytotoxic dose-dependent effects of genistein and quercetin on human LNCaP prostate cancer cells. Mol Pharmacol 2002;62(5):1027-35 (Pubitemid 35229971)
48. Armstrong AJ, Carducci MA. New drugs in prostate cancer. Curr Opin Urol 2006;16(3):138-45 (Pubitemid 43791781)
49. Sonpavde G, Hutson TE, Berry WR. Hormone refractory prostate cancer: management and advances. Cancer Treat Rev 2006;32(2):90-100 (Pubitemid 43362230)
50. Rick FG, Block NL, Schally AV. An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer. Onco Targets and Therapy 2013;6:391-402
51. Van Poppel H, Klotz L. Gonadotropin-releasing hormone: an update review of the antagonists versus agonists. Int J Urol 2012;19:594-601
52. Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 2008;8(4):440-8
53. Heidegger I, Massoner P, Eder IE, et al. Novel therapeutic approaches for the treatment of castration-resistant prostate cancer. J Steroid Biochem Mol Biol 2013;138C:248-56
54. Acar O, Esen T, Lack N. New therapeutics to treat castrate-resistant prostate cancer. Sci World J 2013;2013:379641
55. Sharifi N. Hormonal therapy for prostate cancer: toward further unraveling of androgen receptor function. Anticancer Agents Med Chem 2009;9:1046-51
56. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367(13):1187-97
57. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324(5928):787-90
58. Scher HI, Anand A, Rathkopf D, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010;375(9724):1437-46
59. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Enld J Med 2004;351:1502-12 (Pubitemid 39315317)
60. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advance refractory prostate cancer. N Engl J Med 2004;351:1513-20 (Pubitemid 39315318)
61. Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advance prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008;26:242-6
62. Armstrong AJ, George DJ. Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cnacer. Prostate Cancer Prostatic Dis 2010;13:108-16
63. Yap TA, Pezaro CJ, de Bono JS. Cabazitaxel in metastatic castration-resistant prostate cancer. Expert Rev Anticancer Ther 2012;12(9):1129-36
64. Zhong L, Pon V, Srinivas S, et al. Therapeutic options in docetaxel-refractory metastatic castration-resistant prostate cancer: a cost-effectiveness analysis. PLoS ONE 2013;8(5):e64275
65. Bahl A, Masson S, Birtle A, et al. Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents. Cancer Treat Rev 2013; Epub ahead of print
66. Wu Y, Rosenberg JE, Taplin ME. Novel and new therapeutics in castration-resistant prostate cancer. Curr Opin Oncol 2011;23(3):290-6
67. Maluf F, Smaletz O, Herchenhorn D. Castration-resistant prostate cancer: systemic therapy in 2012. Clinics 2012;67(4):389-94
68. Clarke NW. Landmarks in non-hormonal pharmacological therapies for castration-resistant prostate cancer. BJU Int 2012;110(Suppl 1):14-22
69. Choy H, Park C, Yao M. Current status and future prospects for satraplatin, an oral platinum analogue. Clin Cancer Res 2008;14(6):1633-8 (Pubitemid 351469447)
70. Kawabata R, Oie S, Takahashi M, et al. Up-regulation of insulin-like growth factor-binding protein 3 by 5-fluorouracil (5-FU) leads to the potent anti-proliferative effect of androgen deprivation therapy combined with 5-FU in human prostate cancer cell lines. Int J Oncol 2011;38(6):1489-500
71. Toren P, Gleave M. Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer. Asian J Androl 2013;15:342-9
72. Loriot Y, Zoubeidi A, Gleave ME. Targeted therapies in metastatic castration-resistant prostate cancer: beyond the androgen receptor. Urol Clin North Am 2012;39(4):517-31
73. Dayyani F, Varkaris A, Araujo JC, et al. Increased serum insulin-like growth factor-1 levels are associated with prolonged response to dasatinib-based regimens in metastatic prostate cancer. Prostate 2013;73:979-85
74. De Coster R, Wouters W, Bruynseels J. P450-dependent enzymes as targets for prostate cancer therapy. J Steroid Biochem Mol Biol 1996;56(1-6 Spec No):133-43 (Pubitemid 26107887)
75. Vis A, Schroder F. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways. BJU Int 2009;104(4):438-48
76. Attard G, Richards J, de Bono J. New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin Cancer Res 2011;17(7):1649-57
77. Gardner TA, Elzey BD, Hahn NM. Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer. Hum Vaccin Immunother 2012;8(4):534-9
78. Kantoff P, Higano CS. Integration of immunotherapy into the management of advanced prostate cancer. Urol Oncol 2012;30(5 Suppl):S41-7
79. Rajpar S, Fizazi K. Bone targeted therapies in metastatic castration-resistant prostate cancer. Cancer J 2013;19(1):66-70
80. Vengalil S, O'Sullivan JM, Parker CC. Use of radionuclides in metastatic prostate cancer: pain relief and beyond. Curr Opin Support Palliat Care 2012;6(3):310-15
81. Schrijvers D. Androgen-independent prostate cancer. Recent Results Cancer Res 2007;175:239-49
82. Bohl CE, Gao W, Miller DD, et al. Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci USA 2005. 102:6201
83. Goto T, Ohta K, Fujii S, et al. Design and synthesis of androgen receptor full antagonists bearing a p-carborane cage: promising ligands for anti-androgen withdrawal syndrome. J Med Chem 2012;53:4917-26
84. Josan JS, Katzenellenbogen JA. Designer anti-androgens join the race against drug resistance. ELife 2013;2:e00692
85. Shen HC, Shanmugasundaram K, Simon NI, et al. In silico discovery of androgen receptor antagonists with activity in castration resistant prostate cancer. Mol Endocrinol 2012;26(11):1836-46
86. Voet A, Helsen C, Zhang KY, et al. The discovery of novel human androgen receptor antagonist chemotypes using a combined pharmacophore screening procedure. Chem Med Chem 2013;8:644-51
87. Dart Therapeutics LLC. Imidazolidine compounds as androgen receptor modulators. US 8383608 B2; 2013